ReviewClinical ophthalmology (Auckland, N.Z.)2023
Glaucoma and Dry Eye Disease: Opportunity to Assess and Treat.
Review in Clinical ophthalmology (Auckland, N.Z.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07690397 (GLAUCO-TECH Study), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
GLAUCO-TECH Study: Safety & Efficacy of Preservative-free vs. Preserved Dorzolamide-Timolol-Brimonidine. Impact on the Ocular Surface, Glaucoma Progression, Tear Proteomics, and AI/Chatbot-led Patient Follow-up.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Fifteen-Month Outcomes of Preservative-Free Latanoprost Cationic Emulsion in Open-Angle Glaucoma and Ocular Hypertension: Phase III Open-Label Extension of a Randomized Trial.Clinical ophthalmology (Auckland, N.Z.) · 2025Trial
- Effects of Trehalose, Sodium Hyaluronate and N-Acetyl Aspartyl-Glutamic Acid Artificial Tears on Ocular Surface Parameters in Glaucoma Patients Receiving Preserved and Preservative-Free Prostaglandins.Journal of clinical medicine · 2026Article
- Mental health burden associated with specific ocular conditions among Medicare Advantage beneficiaries with type 2 diabetes: examining the impact of glaucoma, cataracts, retinopathy, and dry eye on unhealthy mental health days.Frontiers in public health · 2026Article
- Potential Influence of Helicobacter Pylori on Glaucoma-Related Alterations of Ocular Surface Microbiota and Dry Eye Disease Pathophysiology.Investigative ophthalmology & visual science · 2025Article
- Results of a Targeted Glaucoma Screening Project Conducted Outside Formal Healthcare Settings in Croatia.Journal of clinical medicine · 2025Article
- Quasi-3D Mechanistic Model for Predicting Eye Drop Distribution in the Human Tear Film.Bioengineering (Basel, Switzerland) · 2025Article
- Alterations of ocular surface microbiome in glaucoma and its association with dry eye.Journal of medical microbiology · 2025Article
- Prevalence, Incidence, and Treatment Characteristics of Primary Open-Angle Glaucoma Among Medicare Fee-for-Service Beneficiaries.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Real-Life Study on the Efficacy and Tolerance of a Preservative-Free Surfactant-Free Latanoprost Eye Drop in Patients with Glaucoma.Ophthalmology and therapy · 2024Article
- Article
- Management of Glaucoma-Related Dry Eye Disease with Intense Pulsed Light: A Randomized Control Study.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Therapeutic effects of Ghrita Manda Ashchyotana on tear film stability, corneal integrity, and IL-6 expression in a benzalkonium chloride-induced murine dry eye model.Journal of Ayurveda and integrative medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye disease (DED) has been found to occur at a higher prevalence in individuals with glaucoma than in individuals without glaucoma. The relationship between glaucoma and DED may be, in part, a result of glaucoma therapy. Greater number of antiglaucoma medications used and greater number of antiglaucoma eyedrops instilled per day have been associated with ocular surface disease in patients with glaucoma. Use of antiglaucoma medication has also been associated with higher levels of ocular surface inflammatory markers and ocular surface alterations. There is evidence to suggest that antiglaucoma medications with preservatives and, to some extent, antiglaucoma medication formulations without preservatives may contribute to ocular surface signs and symptoms. Trabeculectomy for glaucoma has also been associated with ocular surface signs related to DED; however, there may be benefits of trabeculectomy and other procedures for glaucoma due to reduced use of antiglaucoma medications. Patients with glaucoma with ocular surface disease have been found to have greater ocular surface symptoms, poorer vision-related quality of life, and poorer antiglaucoma medication adherence compared with patients with glaucoma without ocular surface disease. Because of the potential negative impact of DED on patients with glaucoma, patients with glaucoma may benefit from evaluation for DED. Management of DED in patients with glaucoma may include modifications to antiglaucoma medications and use of treatments for DED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.